101 related articles for article (PubMed ID: 30352570)
1. Co-expression of nuclear P38 and hormone receptors is prognostic of good long-term clinical outcome in primary breast cancer and is linked to upregulation of DNA repair.
Johnston SJ; Ahmad D; Aleskandarany MA; Kurozumi S; Nolan CC; Diez-Rodriguez M; Green AR; Rakha EA
BMC Cancer; 2018 Oct; 18(1):1027. PubMed ID: 30352570
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
4. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
[TBL] [Abstract][Full Text] [Related]
5. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
[TBL] [Abstract][Full Text] [Related]
6. Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Mazzotta A; Partipilo G; De Summa S; Giotta F; Simone G; Mangia A
Tumour Biol; 2016 May; 37(5):6143-53. PubMed ID: 26614429
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
Alshareeda AT; Negm OH; Albarakati N; Green AR; Nolan C; Sultana R; Madhusudan S; Benhasouna A; Tighe P; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2013 Jun; 139(2):301-10. PubMed ID: 23624778
[TBL] [Abstract][Full Text] [Related]
8. Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer.
Fagerholm R; Sprott K; Heikkinen T; Bartkova J; Heikkilä P; Aittomäki K; Bartek J; Weaver D; Blomqvist C; Nevanlinna H
Ann Oncol; 2013 Nov; 24(11):2780-5. PubMed ID: 23897704
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways.
Schmitz KJ; Callies R; Wohlschlaeger J; Kimmig R; Otterbach F; Bohr J; Lee HS; Takeda A; Schmid KW; Baba HA
J Clin Pathol; 2006 Jul; 59(7):685-91. PubMed ID: 16497869
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer.
Linderholm BK; Hellborg H; Johansson U; Skoog L; Lehtiö J
Breast Cancer Res Treat; 2011 Jan; 125(2):457-65. PubMed ID: 21110084
[TBL] [Abstract][Full Text] [Related]
11. High nuclear MSK1 is associated with longer survival in breast cancer patients.
Pu X; Storr SJ; Ahmad NS; Rakha EA; Green AR; Ellis IO; Martin SG
J Cancer Res Clin Oncol; 2018 Mar; 144(3):509-517. PubMed ID: 29327245
[TBL] [Abstract][Full Text] [Related]
12. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
14. The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma.
Davidson B; Konstantinovsky S; Kleinberg L; Nguyen MT; Bassarova A; Kvalheim G; Nesland JM; Reich R
Gynecol Oncol; 2006 Sep; 102(3):453-61. PubMed ID: 16494928
[TBL] [Abstract][Full Text] [Related]
15. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
16. Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer.
Fohlin H; Pérez-Tenorio G; Fornander T; Skoog L; Nordenskjöld B; Carstensen J; Stål O
Eur J Cancer; 2013 Apr; 49(6):1196-204. PubMed ID: 23305873
[TBL] [Abstract][Full Text] [Related]
17. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
18. Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins.
Merlin JL; Harlé A; Lion M; Ramacci C; Leroux A
Oncol Rep; 2013 Oct; 30(4):1943-8. PubMed ID: 23900300
[TBL] [Abstract][Full Text] [Related]
19. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
20. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]